Nicoletta Loggia
Directeur Technique/Scientifique/R&D chez ORCHARD THERAPEUTICS PLC
Postes actifs de Nicoletta Loggia
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ORCHARD THERAPEUTICS PLC | Directeur Technique/Scientifique/R&D | 09/09/2021 | - |
| CANDEL THERAPEUTICS, INC. | Directeur/Membre du Conseil | 07/06/2023 | - |
| Independent Dir/Board Member | 07/06/2023 | - |
Historique de carrière de Nicoletta Loggia
Formation de Nicoletta Loggia
| University of Pavia | Doctorate Degree |
Statistiques
Internationale
| Royaume-Uni | 2 |
| Italie | 2 |
| Etats-Unis | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Nicoletta Loggia
- Expérience
